Client News

Roquefort Therapeutics PLC: Publication of Prospectus
Home / Client News / Roquefort Therapeutics PLC: Publication of Prospectus

Roquefort Therapeutics (LSE:ROQ,OTCQB:ROQAF), the Main Market listed biotech company focused on early-stage opportunities in the biotechnology sector, is pleased to announce that, further to the conditional share sale and purchase agreement (the “Acquisition Agreement”) with the shareholders of Oncogeni Limited (the “Sellers”) as announced on 22 June 2022, the Company has today received approval from the FCA of its prospectus (the “Prospectus”) and published its Prospectus in relation to the proposed acquisition of the entire issued share capital of Oncogeni Limited (“Oncogeni”), the conditional placing for new Ordinary Shares to raise gross proceeds of £1,015,000 (the “Placing”) and the issue of Consideration Shares (as described below).


If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.


Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.

Share This